

## Mood Disorder Challenges: Emerging Systems and Individual Solutions

Time (CT)	Schedule	Tonico	Speakers	Location
Time (CT)		Topics	эреакего	Location
7:30-8:30am	NNDC Mood Outcomes Program Meeting			Magnolia
7:30-8:30am	Registration, Check-In, Breakfast			Live Oak Pre-Function & Ballroom C&D
8:30-9:00am	Welcome	Welcome Address and NNDC Administrative Updates	NNDC Leadership	Live Oak Ballroom A&B
9:00-9:30am	Symposium: Improving Access for Children	We Will Board You Now: Keeping Kids in Crisis in the ER (25 min talk, 5 min Q&A)	Elizabeth K. Reynolds, PhD, Johns Hopkins Medicine	Live Oak Ballroom A&B
9:30-10:00am	Symposium: Improving Access for Children	MC3 and Mi: Accessing Child Psychiatry Across an Entire State (25 min talk, 5 min Q&A)	Joanna Quigley, MD, University of Michigan	Live Oak Ballroom A&B
10:00-10:30am	Symposium: Improving Access for Children	Solutions: Panel Discussion with Audience Feedback	Session Chair: Heather Flynn, PhD, Florida State University     Moderator: Sagar Parikh, MD, FRCPC, University of Michigan, NNDC Medical Director	Live Oak Ballroom A&B
10:30-11:00am	Break			Live Oak Pre-Function
11:00am-12:00pm	Plenary Talk	Novel and Emerging Antidepressant Medications (45 min talk, 15 min Q&A)	Michael E. Thase, MD, University of Pennsylvania	Live Oak Ballroom A&B
12:00-12:45pm	Lunch			Live Oak Pre-Function & Ballroom C&D
12:45-2:00pm	Poster Session			Live Oak Pre-Function
2:00-2:30pm	Mini-Symposia 1: Non- Traditional Treatments	Optimizing TMS for Psychiatry: Targeting, Mechanisms, and Beyond (25 min talk, 5 min Q&A)	Nicholas T. Trapp, MD, MS, University of lowa	Live Oak Ballroom A&B
2:30-3:00pm	Mini-Symposia 1: Non- Traditional Treatments	The Promise and Perils of Psychedelic-Assisted Therapy (25 min talk, 5 min Q&A)	Benjamin R. Lewis, MD, University of Utah	Live Oak Ballroom A&B
3:00-3:30pm	Break			Live Oak Pre-Function
3:30-4:00pm	Mini-Symposia 2: Technology and Depression	Internet CBT: The Computer Will See You Now (25 min talk, 5 min Q&A)	Isabelle Rosso, PhD, McLean Hospital - Harvard Medical School	Live Oak Ballroom A&B
4:00-4:30pm	Mini-Symposia 2: Technology and Depression	Digital Mental Health Interventions: Promoting or Diminishing Health Equity? (25 min talk, 5 min Q&A)	Rebecca Feinstein MPH, MSW, PhD, University of Illinois at Chicago	Live Oak Ballroom A&B
4:30-4:50pm	Hot Topics	Precision Psychiatry: Imaging Neuroimmune Markers in Major Depression (15 min talk, 5 min Q&A)	Jennifer M. Coughlin, MD, Johns Hopkins Medicine	Live Oak Ballroom A&B
4:50-5:10pm	Hot Topics	College Mental Health: Putting the Oxygen Mask on First for Faculty and Staff (15 min talk, 5 min Q&A)	Michelle B. Riba, MD, MS, University of Michigan	Live Oak Ballroom A&B
5:10-5:30pm	Hot Topics	Developing a Potential New Treatment Alternative for TRD Patients: Psilocybin Assisted Therapy (15 min talk, 5 min Q&A)	Jair C. Soares, MD, PhD, UTHealth Houston, NNDC Vice President	Live Oak Ballroom A&B
5:30-6:30pm	NNDC Networking Happy Hour			Live Oak Pre-Function
5:30-8:30pm	Dinner and Award Ceremony			Live Oak Ballroom B,C,D

## Objectives - Friday, October 13, 2023 Agenda - NNDC 2023 Annual Conference

Session Time (CT) and Title	Speaker	Objective 1	Objective 2	Objective 3	Objective 4
7:30 - 8:30am					
NNDC Mood Outcomes Program Meeting					
<b>7:30 - 8:30am</b> Registration, Check-In, Breakfast					
8:30 - 9:00am Welcome Address	NNDC Leadership	Welcome attendees and provide information about the conference.	Provide administrative updates.	Share the latest developments within the NNDC Network.	
9:00 - 9:30am We Will Board You Now: Keeping Kids in Crisis in the ER	Elizabeth K. Reynolds, PhD, Johns Hopkins Medicine	Understand the current status of youth mental health and need for timely access to care.	Describe the pediatric psychiatry ER boarding crisis.	Consider solutions to the access and resource problems in child mental health.	
9:30 - 10:00am MC3 and Mi: Accessing Child Psychiatry Across an Entire State	Joanna Quigley, MD, University of Michigan	Discuss the demands on access for child and adolescent psychiatric expertise both nationally, and locally.	Review the history and implementation of the MC3 statewide access program.	Review data from this program and discuss opportunities for improving access to care, and having greater impacts at the local level.	
10:00 - 10:30am Solutions: Panel Discussion with Audience Feedback	Session Chair: Heather Flynn, PhD, Florida State University Moderator: Sagar Parikh, MD, University of Michigan, NNDC Medical Director	Identify challenges in pediatric psychiatry access.	Clarify Michigan approach to child psychiatry outreach.	Identify broad systems solutions to access issues.	
<mark>10:30 - 11:00am</mark> Break					
11:00am - 12:00pm Novel and Emerging Antidepressant Medications	Michael E. Thase, MD, University of Pennsylvania	Be able to articulate the major unmet needs in the pharmacotherapy of depression, which serve as potential targets for novel medication development.	Be able to describe the discovery of the antidepressant effects of intravenous ketamine and subsequent efforts to develop other drugs that target glutamatergic neurotransmission.	Discuss the novel neurotransmitter effects of selected neurosteroid and their promise as antidepressants.	Summarize the state of the art of so-called psychedelic compounds that have antidepressant effects, including important unresolved questions and potential challenges.
<b>12:00 - 12:45pm</b> Lunch					
12:45 - 2:00pm Poster Session		Forum for researchers to share their work and knowledge about depression and mood disorders in the categories of Basic Science and Clinical Programs.	An opportunity for early-career researchers to gain feedback from recognized leaders in the mental health field and inspire their colleagues.		
2:00 - 2:30pm Optimizing TMS for Psychiatry: Targeting, Mechanisms, and Beyond	Nicholas T. Trapp, MD, MS, University of Iowa	Discuss current psychiatric indications of transcranial magnetic stimulation.	Explain the state of evidence for various TMS targeting methods for treating major depressive disorder.	Develop an understanding of new methods for exploring the mechanisms underlying repetitive TMS protocols.	
2:30 - 3:00pm The Promise and Perils of Psychedelic-Assisted Therapy	Benjamin R. Lewis, MD, University of Utah	Attendees will develop working knowledge of the current evidence base for psychedelic-assisted therapies.	Attendees will be introduced to some of the major challenges and limitations regarding studies with psychedelic compounds.	Attendees will develop working knowledge of some of the ethical issues presented by psychedelic-assisted therapies.	
<b>3:00 - 3:30pm</b> Break					
3:30 - 4:00pm Internet CBT: The Computer Will See You Now	Isabelle Rosso, PhD, McLean Hospital - Harvard Medical School	Learn about the translation of cognitive behavioral therapy to internet-based delivery.	Learn about the advantage of internet-based CBT.	Understand the current evidence-based for internet-based CBT's efficacy and effectiveness.	
4:00 - 4:30pm Digital Mental Health Interventions: Promoting or Diminishing Health Equity?	Rebecca Feinstein MPH, MSW, PhD, University of Illinois at Chicago	Define health equity within the digital mental health intervention space.	Identify evidence-based models and frameworks to promote health equity.	Illustrate barriers and facilitators to implementing digital mental health interventions.	
4:30 - 4:50pm Precision Psychiatry: Imaging Neuroimmune Markers in Major Depression	Jennifer M. Coughlin, MD, Johns Hopkins Medicine	To share emerging imaging data that may forward our understanding of the role of microglia in Major Depressive Disorder.	To present recent imaging findings in the context of precision psychiatry strategies for care of individuals with Major Depressive Disorder.		
4:50 - 5:10pm College Mental Health: Putting the Oxygen Mask on First for Faculty and Staff	Michelle B. Riba, MD, MS, University of Michigan	Provide a brief history and current issues in college mental health.	Review models of care.	Present the Michigan pilot training faculty and staff.	
5:10 - 5:30pm Developing a Potential New Treatment Alternative for TRD Patients: Psilocybin Assisted Therapy	Jair C. Soares MD, PhD, UTHealth Houston, NNDC Vice President	Learn about recent research involving psychedelic drugs to treat major depression.	Review recent phase II studies of psilocybin in TRD.	Discuss new research avenues with psychedelic agents.	
5:30 - 6:30pm Networking Happy Hour					
<b>6:30 - 8:30pm</b> Dinner and Awards Ceremony					